Subscribe to news

HSCI’s IPO : facts and figures

Date: December 10, 2009
IPO volume: 15 million ordinary shares (20% of increased share capital)
Trading floor: Innovation and Growth Companies (IGC) sector of MICEX
Co-organizers: FINAM CJSC, Russian Funds CJSC
Marker Cap: RUB 712.5 million

  • All the shares offered were placed; demand exceeded supply Offering price –  RUB 9.5 per share
  • Amount raised – RUB 142.5 million (USD 4.8 million)
  • Total number of shareholders: over 300 new shareholders at the IPO;
    1,768 at the record date at April 29, 2011 ->  sufficient liquidity


  • First biotech in Russia to go public
  • The only IPO on the MICEX in 2009
  • Opened trading on the IIM MICEX (Innovation & Investment Market) – «Russian NASDAQ»



HSCI’s IPO in Russian companies’ IPO efficiency ratings (2009-2010)


Providing the best terms for raising capital

Shares behavior after the IPO

The best IPO of an innovative company

  • Ammount raised
  • IPO share price
  • IPO costs
  • MCap dynamics (share price performance relative to the market)
  • Liquidity levels after IPO

all 5 criteria

HSCI ranked




“…It should be noted that three innovative companies demonstrated good results in the ratings where all 15 companies with much better prospects for development were assessed. Human Stem Cells Institute really pretended for being ranked first in two “big” ratings, so its golden prize as “The best IPO of an innovative company” was apparent.”

From the report “Russian companies’ IPO efficiency ratings (2009-2010) prepared by the Center for Capital Market Development upon the request of the Institute for Development of Financial Markets for presentation at IPO&SPO-2010 Forum held on September 23, 2010 in Moscow (